Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × ALK+ Advanced NSCLC × Thoracic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 627 Lung Neoplasms 270 Small Cell Lung Carcinoma 98 Neoplasms 38 Neoplasm Metastasis 32 Adenocarcinoma of Lung 30 Parkinson Disease 4, Autosomal Dominant Lewy Body 20 Brain Neoplasms 19 Carcinoma 17 Breast Neoplasms 16 Mesothelioma, Malignant 14 NSCLC 13 Lung Diseases 13 Thoracic Neoplasms 11 Prostatic Neoplasms 10 Mesothelioma 10 Cachexia 10 Pleural Effusion, Malignant 9 Non-Squamous Non-Small Cell Lung Cancer 9 Adenocarcinoma, Bronchiolo-Alveolar 9 Respiratory Tract Neoplasms 8 Carcinoma, Squamous Cell 8 Bronchial Neoplasms 8 Adenocarcinoma 8 Pancreatic Neoplasms 7 Pain 7 Colonic Neoplasms 7 Carcinoma, Bronchogenic 7 Rectal Neoplasms 6 Non-squamous Non-small Cell Lung Cancer 6

Interventions

brigatinib 1 alectinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03596866 2025-09-12

ALTA-3

Takeda

Phase 3 Completed

248 enrolled 20 charts

ALK+ Advanced NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡